Certain commonly prescribed sleeping pills are associated with a more than fourfold increased risk of death, even among those taking fewer than 18 doses a year, indicates research published in the online journal BMJ Open.
And these drugs are also associated with a significantly increased risk of cancer among those taking high doses, the study shows.
In 2010 between one in 20 and one in 10 adults took a sleeping pill in the US alone, say the authors, who tracked the survival of over 10,500 people with a range of underlying conditions, who were prescribed a range of sleeping pills for an average of 2.5 years between 2002 and 2007.
The drugs included benzodiazepines, such as temazepam; non-benzodiazepines, such as zolpidem, eszopiclone, and zaleplon; barbiturates; and sedative antihistamines.
The survival of these patients, whose average age was 54, was then compared with that of over 23,500 people matched for age, sex, lifestyle factors, and underlying health problems, but who had not been prescribed sleeping pills over the same period.
After taking account of factors likely to influence the results, including age, sex, weight, lifestyle, ethnicity and previously diagnosed cancer, the results pointed to a link between these drugs and an increased risk of death, even at relatively low doses.
Those prescribed up to 18 doses a year were more than 3.5 times as likely to die as those prescribed none, while those prescribed between 18 and 132 doses were more than four times as likely to do so.
And those taking the most doses (132+ a year) were more than five times as likely to die as those prescribed none, indicating that the level of risk rose in tandem with increasing doses, say the authors.
These associations were found in every age group, but were greatest among those aged 18 to 55.
Supplementary material posted alongside the paper shows that, although the overall numbers of deaths in each group were quite small, there were clear differences among them.
For example, there were 265 deaths among 4,336 people taking zolpidem, compared with 295 deaths among the 23,671 people who had not taken sedatives or sleeping pills.
Those taking the highest number of doses were also at greater risk of developing several types of cancer, and 35% more likely to be diagnosed with any type of cancer, overall. This association was not explained by pre-existing poor health, the data showed.
The authors point out that studies showing association don't necessarily prove cause and effect. But their findings back up previous research showing an increased risk of death among users of sleeping pills, they say.
Agreement is beginning to build that alternatives to sleeping pills for the treatment of insomnia may be warranted, they write.
And they ask if it isn't time to reconsider "whether even the short term use of hypnotics, as given qualified approval in National Institute for Health and Clinical Excellence [NICE] guidance, is sufficiently safe."
BMJ Open editor in chief, Dr Trish Groves, comments: "Although the authors have not been able to prove that sleeping pills cause premature death, their analyses have ruled out a wide range of other possible causative factors. So these findings raise important concerns and questions about the safety of sedatives and sleeping pills."
BMJ-British Medical Journal: http://www.bma.org
This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.
Pharmacology can get a bad rap in the press. Professors George Davey Smith and David Nutt fight the case for statins and SSRIs.
People who spend time watching fish swim in aquarium tanks could improve their physical and mental wellbeing, a study shows.
The chytrid fungus has wiped out populations of amphibians around the world. A type of the fungus infects only salamanders, and researchers have identified vulnerable areas in North America.
NPR's Melissa Block speaks with the AP's Brazil bureau chief Brad Brooks about the investigation, which found high levels of dangerous viruses in water venues for the 2016 Summer Olympics.
Unusual clinical trial in Guinea offers promise for stopping epidemic
Researchers say study suggests need to target black men for screening of prostate cancer, which is projected to become the UK’s most common cancer by 2030 Black men in England have twice the lifetime risk of both being diagnosed with – and dying from – prostate cancer compared with white men, according to a study by Public Health England and Prostate Cancer UK.
MERS causes only mild symptoms in monkeys, so although the vaccine seemed to reduce their symptoms, it's hard to know if this will apply to humans as well
The World Health Organisation is doing its final checks and could declare Nigeria officially free of polio by September. Somalia could be next
Researchers in Hong Kong have cured infected monkeys of MERS using existing drugs
European Medicines Agency recommends RTS,S, or Mosquirix, developed by GSK and backed by Gates Foundation, for use in young children in Africa